secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001493152-24-023834
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LIXTE collaborates with Roche and NKI on trial combining LB-100 with atezolizumab in MSI Low colon cancer
--------------------------------------------------------------------------------

- Trial (NCT06012734) will test LB-100 plus Roche's PD-L1 inhibitor atezolizumab in immunotherapy-unresponsive MSI Low metastatic colon cancer.
- LIXTE provides LB-100; Roche provides atezolizumab via imCORE Network; NKI is principal investigator.
- About 85% of colon cancers are MSI Low; LB-100 may sensitize these tumors to immunotherapy, expanding treatment options.
- This is second recent pharma-backed trial combining LB-100 with immunotherapy; GSK is funding a separate trial in clear cell ovarian cancer.
- New pre-clinical data in EMBO Reports showed LB-100 can turn immunologically 'cold' tumors 'hot'.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224023834/0001493152-24-023834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224023834/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-023834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer